#tirzepatide Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Tirzepatide San Antonio, TX |

Consistent with the low rate of study treatment discontinuation, at most 3% of patients who received at least one dose of tirzepatide in SURPASS-1 to -5 discontinued treatment because of nausea, vomiting or diarrhoea [9]

The approval was granted based on demonstrated improvements in MASH and fibrosis, and a confirmatory study is currently underway

What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care Brandon Aylward Oct 16, 2025 10 min read Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s)

Bleeding after menopause: Risk factors While postmenopausal bleeding can have many possible causes, certain health conditions, medications, and other factors may raise the likelihood of it occurring